Get the Stockscreener App
31.06
9.34%
-3.20
After Hours:
31.05
-0.010
-0.03%
Neurogene Inc stock is traded at $31.06, with a volume of 571.65K.
It is down -9.34% in the last 24 hours and up +39.03% over the past month.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
See More
Previous Close:
$34.26
Open:
$31.01
24h Volume:
571.65K
Relative Volume:
3.10
Market Cap:
$443.29M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-3.12%
1M Performance:
+39.03%
6M Performance:
+83.03%
1Y Performance:
-32.58%
1-Day Range:
$27.22
$31.48
1-Week Range:
$27.22
$35.47
52-Week Range:
$6.875
$74.49
Neurogene Inc Stock (NGNE) Company Profile
Name
Neurogene Inc
Sector
Industry
Phone
(877) 237-5020
Address
535 W 24TH STREET, NEW YORK
Compare NGNE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
31.06 | 488.96M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Craig Hallum | Buy |
| May-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Mar-21-24 | Initiated | William Blair | Outperform |
| Jan-08-24 | Initiated | H.C. Wainwright | Buy |
| Jan-05-24 | Initiated | Stifel | Buy |
| Jan-04-24 | Initiated | TD Cowen | Outperform |
View All
Neurogene Inc Stock (NGNE) Latest News
How to use a screener to detect Neurogene Inc. breakoutsJuly 2025 Price Swings & Consistent Growth Equity Picks - newser.com
Is Neurogene Inc. stock a buy on dipsWeekly Earnings Recap & Safe Entry Momentum Tips - newser.com
Why Neurogene Inc. (UU8) stock could be top winnerQuarterly Performance Summary & Risk Adjusted Swing Trade Ideas - newser.com
Tools to monitor Neurogene Inc. recovery probabilityTrade Exit Summary & Consistent Growth Stock Picks - newser.com
Applying big data sentiment scoring on Neurogene Inc.2025 Trade Ideas & Fast Entry Momentum Trade Alerts - newser.com
Is Neurogene Inc. (UU8) stock among top earnings playsDip Buying & Safe Swing Trade Setups - newser.com
Using AI based signals to follow Neurogene Inc.Trade Analysis Summary & Safe Capital Growth Trade Ideas - newser.com
Can Neurogene Inc. (UU8) stock sustain institutional flowsQuarterly Performance Summary & Low Risk High Win Rate Stock Picks - newser.com
Will Neurogene Inc. (UU8) stock profit from automation waveJuly 2025 Pullbacks & Proven Capital Preservation Tips - newser.com
Why Neurogene Inc. stock could outperform in 2025July 2025 Recap & High Conviction Buy Zone Picks - newser.com
Will Neurogene Inc. stock outperform growth indexesEarnings Growth Summary & Verified Momentum Watchlists - newser.com
Why Neurogene Inc. stock is popular among millennialsEarnings Trend Report & Weekly Breakout Watchlists - newser.com
Why Neurogene Inc. stock remains a top recommendationWeekly Investment Summary & Risk Adjusted Buy/Sell Alerts - newser.com
Signal strength of Neurogene Inc. stock in tech scanners2025 Volume Leaders & Free Verified High Yield Trade Plans - newser.com
Risk adjusted return profile for Neurogene Inc. analyzedEntry Point & Long-Term Capital Growth Strategies - newser.com
Does Neurogene Inc. qualify in momentum factor screeningBond Market & AI Based Buy/Sell Signal Reports - newser.com
Why Neurogene Inc. stock remains undervaluedPortfolio Value Report & AI Powered Market Trend Analysis - newser.com
Is Neurogene Inc. (UU8) stock supported by strong fundamentalsGlobal Markets & Stepwise Trade Execution Plans - newser.com
Will Neurogene Inc. (UU8) stock keep high P E multiplesPortfolio Return Summary & Expert Approved Momentum Trade Ideas - newser.com
Volume spikes in Neurogene Inc. stock – what they meanJuly 2025 Catalysts & Community Consensus Stock Picks - newser.com
Is Neurogene Inc. (UU8) stock a buy before new product rollout - newser.com
Price action breakdown for Neurogene Inc.July 2025 Sector Moves & Verified Swing Trading Watchlists - newser.com
Why Neurogene Inc. (UU8) stock could break out in 20252025 Trading Recap & Daily Profit Maximizing Tips - newser.com
Combining price and volume data for Neurogene Inc.July 2025 Closing Moves & Stepwise Entry/Exit Trade Alerts - newser.com
Neurogene Inc. $NGNE Shares Bought by Jennison Associates LLC - MarketBeat
Neurogene Inc Stock (NGNE) Financials Data
There is no financial data for Neurogene Inc (NGNE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):